NEW YORK (GenomeWeb) – Epigenomics today said that its third quarter revenues grew 7 percent year over year as the firm progresses in its efforts to gain regulatory approval of its colorectal cancer molecular diagnostic test.

For the three months ended Sept. 30, the firm recorded revenues of €284,000 ($353,000), up from €263,000 in the year-ago quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.